213 related articles for article (PubMed ID: 23560825)
1. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries.
Godman B; Wettermark B; Miranda J; Bennie M; Martin A; Malmström RE
Int J Clin Pract; 2013 Sep; 67(9):853-62. PubMed ID: 23560825
[TBL] [Abstract][Full Text] [Related]
2. Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries.
Hesse U; Godman B; Petzold M; Martin A; Malmström RE
Appl Health Econ Health Policy; 2013 Dec; 11(6):677-85. PubMed ID: 24105097
[TBL] [Abstract][Full Text] [Related]
3. Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?
Kalaba M; Godman B; Vuksanović A; Bennie M; Malmström RE
J Comp Eff Res; 2012 Nov; 1(6):539-49. PubMed ID: 24236473
[TBL] [Abstract][Full Text] [Related]
4. Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland?
Bennie M; Bishop I; Godman B; Campbell S; Miranda J; Finlayson AE; Gustafsson LL
Qual Prim Care; 2013; 21(1):7-15. PubMed ID: 23735629
[TBL] [Abstract][Full Text] [Related]
5. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future.
Vončina L; Strizrep T; Godman B; Bennie M; Bishop I; Campbell S; Vlahović-Palčevski V; Gustafsson LL
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):469-79. PubMed ID: 21831028
[TBL] [Abstract][Full Text] [Related]
6. Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries.
Bucsics A; Godman B; Burkhardt T; Schmitzer M; Malmström RE
Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):809-19. PubMed ID: 23252361
[TBL] [Abstract][Full Text] [Related]
7. Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications.
Bennie M; Bishop I; Godman B; Barbui C; Raschi E; Campbell S; Miranda J; Gustafsson LL
Int J Clin Pract; 2013 Feb; 67(2):170-80. PubMed ID: 23305478
[TBL] [Abstract][Full Text] [Related]
8. Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications.
Martin A; Godman B; Miranda J; Tilstone J; Saleem N; Olsson E; Acosta A; Restrepo L; Bennie M
J Comp Eff Res; 2014 Jan; 3(1):41-51. PubMed ID: 24345256
[TBL] [Abstract][Full Text] [Related]
9. Changes in the utilization of venlafaxine after the introduction of generics in Sweden.
Godman B; Persson M; Miranda J; Skiöld P; Wettermark B; Barbui C; Gustafsson LL
Appl Health Econ Health Policy; 2013 Aug; 11(4):383-93. PubMed ID: 23754677
[TBL] [Abstract][Full Text] [Related]
10. Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries.
Godman B; Bucsics A; Burkhardt T; Schmitzer M; Wettermark B; Wieninger P
Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):199-207. PubMed ID: 20384566
[TBL] [Abstract][Full Text] [Related]
11. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions.
Markovic-Pekovic V; Skrbić R; Godman B; Gustafsson LL
Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):661-71. PubMed ID: 23186404
[TBL] [Abstract][Full Text] [Related]
12. The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium.
Fraeyman J; Van Hal G; Godman B; Beutels P
Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):141-51. PubMed ID: 23402454
[TBL] [Abstract][Full Text] [Related]
13. Different initiatives across Europe to enhance losartan utilization post generics: impact and implications.
Moon JC; Godman B; Petzold M; Alvarez-Madrazo S; Bennett K; Bishop I; Bucsics A; Hesse U; Martin A; Simoens S; Zara C; Malmström RE
Front Pharmacol; 2014; 5():219. PubMed ID: 25339902
[TBL] [Abstract][Full Text] [Related]
14. Generic atypical antipsychotic drugs in Belgium: their influence and implications.
Godman B; De Bruyn K; Miranda J; Raschi E; Bennie M; Barbui C; Simoens S
J Comp Eff Res; 2013 Nov; 2(6):551-61. PubMed ID: 24236794
[TBL] [Abstract][Full Text] [Related]
15. Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.
Godman B; Petzold M; Bennett K; Bennie M; Bucsics A; Finlayson AE; Martin A; Persson M; Piessnegger J; Raschi E; Simoens S; Zara C; Barbui C
BMC Med; 2014 Jun; 12():98. PubMed ID: 24927744
[TBL] [Abstract][Full Text] [Related]
16. Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis.
Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
Circ Cardiovasc Qual Outcomes; 2017 Oct; 10(10):. PubMed ID: 28974512
[TBL] [Abstract][Full Text] [Related]
17. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications.
McGinn D; Godman B; Lonsdale J; Way R; Wettermark B; Haycox A
Expert Rev Pharmacoecon Outcomes Res; 2010 Feb; 10(1):73-85. PubMed ID: 20121565
[TBL] [Abstract][Full Text] [Related]
18. The Utilization, Expenditure, and Price of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the US Medicaid Programs: Trends Over a 31 Year Period.
Almadfaa RO; Wigle PR; Hincapie AL; Guo JJ
Int J Cardiol; 2023 Jan; 370():412-418. PubMed ID: 36306953
[TBL] [Abstract][Full Text] [Related]
19. Impact of drug price adjustments on utilization of and expenditures on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in Taiwan.
Huang SH; Hsu CN; Yu SH; Cham TM
BMC Public Health; 2012 May; 12():288. PubMed ID: 22521158
[TBL] [Abstract][Full Text] [Related]
20. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications.
Godman B; Wettermark B; van Woerkom M; Fraeyman J; Alvarez-Madrazo S; Berg C; Bishop I; Bucsics A; Campbell S; Finlayson AE; Fürst J; Garuoliene K; Herholz H; Kalaba M; Laius O; Piessnegger J; Sermet C; Schwabe U; Vlahović-Palčevski VV; Markovic-Pekovic V; Vončina L; Malinowska K; Zara C; Gustafsson LL
Front Pharmacol; 2014; 5():106. PubMed ID: 24987370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
